Evaluating vascular aging after COVID-19 infection
Covid-19 Effects on ARTErial StIffness and Vascular AgiNg
This study is testing how COVID-19 affects blood vessel health and aging in adults by checking their heart and blood vessel function six and twelve months after infection.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 360 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 3 sites (Nancy and 2 other locations) |
| Trial ID | NCT04558450 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the effects of COVID-19 on arterial stiffness and vascular aging by conducting non-invasive evaluations of vascular and cardiac function in patients six and twelve months post-infection. Eligible participants will include adults diagnosed with COVID-19, with varying degrees of hospitalization, and will undergo assessments to measure carotid-femoral pulse-wave velocity. Additionally, cardiovascular events and mortality data will be collected over a period of 10 years to understand long-term impacts.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years old who have recently been diagnosed with COVID-19 and have varying hospitalization experiences.
Not a fit: Patients under 18 years old, those unable to provide consent, or with life-limiting conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the long-term cardiovascular effects of COVID-19, potentially leading to improved management and treatment strategies for affected patients.
How similar studies have performed: Other studies have explored the cardiovascular effects of COVID-19, indicating a growing body of evidence, but this specific approach to vascular aging is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age \>18 years, both sexes; * written informed consent; * affiliation to a social security regime; * a recent diagnosis of COVID19 (6±3 months) proven by PCR or serology (for group 1,2,3) * hospitalization in intensive care unit for COVID19 (for group 1) * hospitalization in a medicine unit for COVID19 (for group 2) * no hospitalization for COVID19 or hospitalization less than 24h (for group 3) * a negative test for SARS-nCOV2 infection (PCR or serology)(for group 4) Exclusion Criteria: * Age \<18 years * Inability to express consent of the study * Diseases carrying out a life -expectancy \<1 year according to clinical judgment * Pregnancy and breastfeeding * Foreseen inability to attend scheduled visits
Where this trial is running
Nancy and 2 other locations
- CHRU Nancy — Nancy, France (Recruiting)
- Hôpital Européen Georges Pompidou - APHP — Paris, France (Recruiting)
- CHU Rouen — Rouen, France (Recruiting)
Study contacts
- Principal investigator: Pierre BOUTOUYRIE, MD PHD — Assistance Publique - Hôpitaux de Paris
- Study coordinator: Rosa Maria BRUNO, MD
- Email: rosa-maria.bruno@inserm.fr
- Phone: +33 1 53 98 79 67
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.